[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616988":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":35,"locations":41,"responsibleParty":52,"collaborators":26,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":26,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":26,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":26,"overallStatus":75,"whyStopped":26,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A","EXPERIMENTAL","Period 1 : Treatment A(AD-231A), Period 2 : Treatment C(AD-231A+AD-231B+AD-231C)",[13,14],"Drug: Treatment A(AD-231A)","Drug: Treatment C(AD-231A+AD-231B+AD-231C)",{"label":16,"type":10,"description":17,"interventionNames":18},"Arm B","Period 1 : Treatment B(AD-231B+AD-231C), Period 2 : Treatment C(AD-231A+AD-231B+AD-231C)",[19,14],"Drug: Treatment B(AD-231B+AD-231C)",[21,27,31],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Treatment A(AD-231A)","AD-231A Oral Tablet",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Treatment B(AD-231B+AD-231C)","AD-231B+AD-231C Oral Tablet",[16],{"type":22,"name":32,"description":33,"armGroupLabels":34,"otherNames":26},"Treatment C(AD-231A+AD-231B+AD-231C)","AD-231A+AD-231B+AD-231C Oral Tablet",[9,16],[36],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"JaeHun Jung","CONTACT","+8247679615","jhjung@addpharma.co.kr",[42],{"facility":43,"status":26,"city":44,"state":26,"zip":26,"country":45,"countryCode":26,"cosmosGeoPoint":46,"geoPoint":51,"contacts":26},"H+ Yangji Hospital","Seoul","South Korea",{"type":47,"coordinates":48},"Point",[49,50],126.9784,37.566,{"lat":50,"lon":49},{"type":53,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100616988","phase-1-a-study-to-evaluate-the-pharmacokinetic-interaction-and-the-safety-of-ad-231a-and-ad-231b-and-ad-231c-100616988",false,"NCT07312773","A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C","A Two-arm, Open-label, Single-sequence, Multiple-dose Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy adult volunteers aged ≥19 and \\\u003C65 years at the time of the screening visit\n* Body weight ≥50 kg (≥45 kg for females) and body mass index (BMI) between 18.0 kg\u002Fm² and 30.0 kg\u002Fm² at the time of the screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"ALL","19 Years","64 Years",{"count":66,"type":67},55,"ESTIMATED","INTERVENTIONAL",[70],"PHASE1","To evaluate the pharmacokinetic interactions of AD-231A, AD-231B, and AD-231C in healthy adult volunteers.",[73,74],"Hypertension","Hyperlipidemia","NOT_YET_RECRUITING","2025-12-17",{"date":78,"type":79},"2025-12-31","ACTUAL",{"date":81,"type":67},"2026-01-23",{"date":83,"type":67},"2026-02-22",{"name":5,"class":6},1]